Results 61 to 70 of about 3,784 (223)

Addressing phenoconversion: the Achilles' heel of personalized medicine [PDF]

British Journal of Clinical Pharmacology, 2014
Phenoconversion is a phenomenon that converts genotypic extensive metabolizers (EMs) into phenotypic poor metabolizers (PMs) of drugs, thereby modifying their clinical response to that of genotypicPMs. Phenoconversion, usually resulting from nongenetic extrinsic factors, has a significant impact on the analysis and interpretation of genotype‐focused ...
Rashmi R. Shah, Robert L. Smith
openalex   +3 more sources

A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimer’s disease [PDF]

GeroScience, 2022
AbstractRecent reports have suggested that the reactivation of otherwise transcriptionally silent transposable elements (TEs) might induce brain degeneration, either by dysregulating the expression of genes and pathways implicated in cognitive decline and dementia or through the induction of immune-mediated neuroinflammation resulting in the ...
Fabìo Macciardi, Maria Giulia Bacalini, Ricardo Miramontes, Alessio Boattini, Cristian Taccioli, Giorgia Modenini, Rond Malhas, Laura Anderlucci, Yuriy Gusev, Thomas Groß, Robert Padilla, Massimo S. Fiandaca, Elizabeth Head, Guia Guffanti, Howard J. Federoff, Mark Mapstone   +15 more
openalex   +6 more sources

Pitfalls and challenges associated with phenoconversion in forensic toxcicology [PDF]

Forensic Science International: Genetics, 2020
In recent years, several publications have demonstrated the interest and the usefulness of pharmacogenetics in forensic toxicology. However, this approach remains namely focused on DNA-based phenotype, which may potentially lead to misinterpretation.
Guillaume Drevin, Nicolas Picard, Nathalie Jousset, Marie Briet, Chadi Abbara   +4 more
openalex   +4 more sources

Clinical and dopaminergic imaging characteristics of the FARPRESTO cohort of trial-ready idiopathic rapid eye movement sleep behavior patients [PDF]

, 2023
Introduction: Idiopathic/isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is considered the prodromal stage of alpha-synucleinopathies. Thus, iRBD patients are the ideal target for disease-modifying therapy. The risk FActoRs PREdictive of
Antelmi, Elena, Arnaldi, Dario, Baldelli, Luca, Bonanni, Enrica, Brunetti, Valerio, Capriglia, Elena, Casaglia, Elisa, Ferini-Strambi, Luigi, Fernandes, Mariana, Figorilli, Michela, Liguori, Claudio, Marelli, Sara, Mattioli, Pietro, Morbelli, Silvia, Pardini, Matteo, Placidi, Fabio, Plazzi, Giuseppe, Provini, Federica, Puligheddu, Monica, Rubino, Annalisa, Rustioni, Valter, Serra, Alessandra, Terzaghi, Michele   +22 more
core   +7 more sources

Unawareness of motor phenoconversion in Huntington disease [PDF]

Neurology, 2013
To determine whether Huntington disease (HD) mutation carriers have motor symptoms (complaints) when definite motor onset (motor phenoconversion) is diagnosed and document differences between the groups with and without unawareness of motor signs.We analyzed data from 550 HD mutation carriers participating in the multicenter PREDICT-HD Study followed ...
Elizabeth A, McCusker, David G, Gunn, Eric A, Epping, Clement T, Loy, Kylie, Radford, Jane, Griffith, James A, Mills, Jeffrey D, Long, Jane S, Paulsen   +8 more
openaire   +2 more sources

Evaluation of changes in cytochrome P450 2C19 activity in type 2 diabetic rats before and after treatment, by using isolated perfused liver model [PDF]

Iranian Journal of Basic Medical Sciences, 2020
Objective(s): Alteration in drug metabolism is very likely in diabetes mellitus. This study assessed changes in CYP2C19 enzymatic activity in the liver using omeprazole as a probe in the animal model of type II diabetes (T2DM) before and after treatment ...
Navid Neyshaburinezhad, Mohammad Reza Rouini, Hanieh Entezari, Hoda Lavasani, Yalda Hosseinzadeh Ardakani   +4 more
doaj   +1 more source

Pharmacogenomic testing and its future in community pharmacy [PDF]

, 2020
Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the
Wright, David, Youssef, Essra
core   +1 more source

Predicting phenoconversion in pure autonomic failure

Neurology, 2020
To determine predicting factors and frequency of phenoconversion from pure autonomic failure (PAF) into a synucleinopathy with motor or cognitive involvement of multiple system atrophy (MSA), Parkinson disease (PD), or dementia with Lewy bodies (DLB).We performed a retrospective review of all patients with PAF from 2001 to 2011 evaluated at Mayo Clinic,
Elizabeth A, Coon, Jay N, Mandrekar, Sarah E, Berini, Eduardo E, Benarroch, Paola, Sandroni, Phillip A, Low, Wolfgang, Singer   +6 more
openaire   +3 more sources

Personality profile and its association with conversion to neurodegenerative disorders in idiopathic REM sleep behavior disorder

npj Parkinson's Disease, 2022
Patients with Parkinson’s disease (PD) were described less extraverted and more neurotic. It remained unclear whether similar personality traits could be found in idiopathic rapid eye movement sleep behavior disorder (iRBD), a prodromal stage of PD, and ...
Li Zhou, Steven W. H. Chau, Yaping Liu, Jing Wang, Jihui Zhang, Ngan Yin Chan, Joey W. Y. Chan, Bei Huang, Sijing Chen, Shirley Xin Li, Vincent Chung Tong Mok, Yun Kwok Wing   +11 more
doaj   +1 more source

The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions

Pharmaceuticals, 2021
Drug interactions are a well-known cause of adverse drug events, and drug interaction databases can help the clinician to recognize and avoid such interactions and their adverse events. However, not every interaction leads to an adverse drug event.
Martina Hahn, Sibylle C. Roll
doaj   +1 more source